Chat with us, powered by LiveChat

Vaccine Technologies Market

Vaccine Technologies Market: By Type (Recombinant & Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines), By End user (Pediatric, Adults, Travelers), By Distribution Channel (Hospital and retail pharmacies, Government suppliers), And Region - Global Analysis of Market Size, Share & Trends For 2019-2020 And Forecasts To 2031

Published on: Feb-2023
Report Code: FG HC 01374
No. of Pages: 170 - 350
Report Format: PDF

[170+ Pages Research Report] Vaccine Technologies Market to surpass USD 121.94 billion by 2031 from USD 52.43 billion in 2021 at a CAGR of 7.4% throughout the forecast period 2022-32

Product Overview

Vaccines or immunizations are injections of a weakened form of a disease into a person, causing the body to produce antibodies or immunity against the disease. Effective immunisation has wiped out a number of diseases with high mortality rates, such as polio and smallpox. Vaccinations play an important role in ensuring people's long-term health in various countries; thus, they are used in a variety of regional disease-prevention strategies. Vaccines are continuing to transform our ability to prevent disease and improve health. With technological advancement, we are able to extend the benefits of vaccines to more people and provide better protection against potentially fatal infectious diseases.

Market Highlights

Global Vaccine Technologies market is expected to project a notable CAGR of 7.4% in 2031.

Global Vaccine Technologies to surpass USD 121.94 billion by 2031 from USD 52.43 billion in 2021 at a CAGR of 7.4% in the coming years, i.e., 2021-31. The high prevalence of infectious diseases, increasing company initiatives to improve vaccine research and development, growing government support for vaccine development, and a growing emphasis on immunisation are all factors driving the growth of this market. Vaccine manufacturers' primary strategies for achieving a significant position in the thriving human vaccines sector are acquisitions, innovation, and collaborations.

Figure - Market Analysis of Global Vaccine Technologies Market

Global Vaccine Technologies: Segments

Conjugate vaccines segment to grow with the highest CAGR during 2021-31

Based on type, global Vaccine Technologies Market is fragmented into Recombinant & Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines and Others. The conjugate vaccines segment held the greatest share of the vaccines market. This segment's large share can be attributed to rising government support and company investments in conjugate vaccine development.

Pediatric providers segment to grow with the highest CAGR during 2021-31

Global Vaccine Technologies market is classified on the basis of end user into Pediatric, Adults, Travelers and Others. Because of the high demand for vaccines in infants, such as MMR vaccines, BCG vaccines and DPT vaccines, the paediatric segment accounted for the majority of the vaccine market share, and this trend is expected to continue during the forecast period. Furthermore, an increase in immunisation awareness about vaccination drives the growth of this vaccine market. Traveler vaccines are also expected to grow at a rapid pace in the near future, owing to their critical role in reducing the risk of exposure to various diseases associated with people travelling to various regions.

Hospital and retail pharmacies segment to grow with the highest CAGR during 2021-31

Based on distribution channel, global Vaccine Technologies Market is segmented into Hospital and retail pharmacies, Government suppliers and Others. Hospital and retail pharmacies segment held the greatest share of the vaccines technology market owing to its availability to the general public as they are under government surveillance. Furthermore, vaccination is often conducted at smaller institutions as it is a shorter duration procedure, which is also expected to fuel segment growth.

Figure - Market Analysis of Global Vaccine Technologies Market

Market Dynamics

Drivers

Improvement in technologies and government initiatives

The development of new vaccine technologies is fueled by sustained investment in innovation, as well as the unwavering commitment of the scientific community. New technologies are developed to not only prevent the re-emergence of infectious diseases that have previously been successfully controlled by immunisation, but also to ensure that the global community is prepared to deal with current and future threats. Furthermore, government initiatives for raising venture capital and funding from healthcare providers to start-ups that provide such services will drive market growth even further.

Increase in infectious diseases and awareness among people

Vaccinations have become more popular in recent years, owing to an increase in the prevalence of both viral and bacterial infectious diseases. Vaccinations are primarily administered to people of various ages in order to strengthen their immune systems and provide protection against various infectious diseases. Furthermore, the rise in the incidence of various infectious diseases, as well as increased awareness about early disease diagnosis and prevention, drive the demand for protective vaccines, boosting market growth.

Restraint

Demand-supply problem and restrictions

Due to high demand for the COVID-19 vaccine, manufacturers are experiencing supply issues, resulting in delays. This could limit market growth to some extent. Furthermore, due to restrictions, the supply of routine vaccines has been disrupted, negatively affecting market progression.

Global Vaccine Technologies:

Key Players

  • Abbott

Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis

  • Serum Institute of India
  • Pfizer
  • Bayer
  • GE Healthcare
  • Glaxosmithkline
  • Johnson and Johnson
  • Thermo Fisher Scientific
  • GlaxoSmithKline plc
  • Other Prominent Players

Global Vaccine Technologies: Regions

Global Vaccine Technologies market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. North America's position in the global vaccines market is attributed to the high prevalence of infectious diseases and increased investments in vaccine development by government and non-government organisations. On the other hand, the APAC region is also expected to grow owing to factors such as rising healthcare costs and disposable income, government initiatives, and the presence of a large patient population are propelling the Asian vaccines market forward.

Impact of Covid-19 on Vaccine Technologies Market

A high level of vaccination awareness is a major driving force in the industry's advancement. High acceptance rates, sophisticated infrastructure, and production capacity will also have a positive impact on growth of vaccine technology over the forecast period. During the COVID-19 pandemic, numerous small and local players emerged to develop COVID-19 vaccines and are constantly undertaking various initiatives to strengthen the distribution chain and expand the customer base.

Global Vaccine Technologies is further segmented by region into:

  • North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
  • Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
  • Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
  • Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
  • Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA

Global Vaccine Technologies report also contains analysis on:

Vaccine Technologies Segments:

  • By Type
    • Recombinant & Conjugate Vaccines
    • Live Attenuated Vaccines
    • Inactivated Vaccines
    • Toxoid Vaccines
    • Others
  • By End user
    • Pediatric
    • Adults
    • Travelers
    • Others
  • By Distribution Channel
    • Hospital and retail pharmacies
    • Government suppliers
    • Others
  • Vaccine Technologies Dynamics
  • Vaccine Technologies Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies Involved in the Market
  • Value Chain of the Market
  • Market Drivers and Restraints

Vaccine Technologies Market Report Scope and Segmentation

REPORT ATTRIBUTE

DETAILS

Market size value in 2021

USD 52.43 billion

Revenue forecast in 2031

USD 121.94 billion

Growth Rate

CAGR of 7.4% from 2021 to 2031

Base year for estimation

2020

Quantitative units

Revenue in USD million and CAGR from 2021 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Type, End user, Distribution channel and Region

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)

Key companies profiled

Abbott, Serum Institute of India, Pfizer, Bayer, GE Healthcare, Glaxosmithkline, Johnson and Johnson and Thermo Fisher Scientific, GlaxoSmithKline plc, and Other Prominent Players             .

 

Frequently Asked Questions (FAQ):

Vaccine Technologies market size was estimated at USD 52.43 billion in 2021 and is expected to reach USD 121.94 billion in 2031.

Vaccines or immunizations are injections of a weakened form of a disease into a person, causing the body to produce antibodies or immunity against the disease.

Hospital and retail pharmacies, conjugate vaccines and pediatric segment accounted for the largest Vaccine Technologies market share.

Key players: Abbott, Serum Institute of India, Pfizer, Bayer, GE Healthcare are the key players in the Vaccine Technologies market.

The high prevalence of infectious diseases, increasing company initiatives to improve vaccine research and development, growing government support for vaccine development, and a growing emphasis on immunisation are all factors driving the growth of this market

Select License Type

$3199

Report accessible by 1 user only

In case you require a hard copy, there will be an additional charge of $500. Please email us at info@fatposglobal.com with your request

Call us

Research Assistance

US : +1 (716) 218-3733
UK : +44 (208) 1235555



Select License Type

$3199

Report accessible by 1 user only

Sample Request

Client Testimonials

FATPOS CLIENT Appriciation DURING THE PROJECT

Clients